secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIOCRYST PHARMACEUTICALS INC (BCRX)
CIK:        0000882796
Form:       8-K
Filed at:   2024-06-13T23:59:59+00:00
Accession:  0001171843-24-003430
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BioCryst shareholders approve 7M-share increase to Stock Incentive Plan
-----------------------------------------------------------------------

- Stockholders approved amendment increasing authorized shares by 7,000,000 to 70,090,000 total under the plan.
- Directors re-elected: Nancy J. Hutson, Vincent J. Milano, A. Machelle Sanders; broker non-votes 26,962,524.
- Ernst & Young ratified as FY 2024 auditor (167,496,029 for); advisory exec-comp resolution passed (138,402,008 for).
- Incentive Plan Proposal passed with 101,846,368 for, 43,055,807 against; plan now includes 12-month minimum vesting.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/882796/000117184324003430/0001171843-24-003430-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/882796/000117184324003430/f8k_061324.htm
  HTML page:      https://secwatch.observer/filing/0001171843-24-003430

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer